|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | How do Chinese medicines that tonify the kidney inhibit dopaminergic neuron apoptosis?显示文摘Wistar rats were intragastrically perfused with Chinese medicines used for tonifying the kidney.These included 0.180 g/mL of Herba Epimedii(Epimedium), Semen Cuscutae(Dodder Seed), or Herba Cistanches(Desertliving Cistanche), 0.04 mg/mL monoamine oxidase-B inhibitor selegiline,or distilled water for 14 consecutive days to prepare drug-containing serum or blank serum.MES23.5 cells in the logarithmic phase were cultured in media supplemented with 15%drug-containing serum for 24 hours, followed by incubation in culture solution containing 100 μmol/L H2O2for 3 hours. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide(MTT) and flow cytometry results showed that all drug-containing serums improved the survival rate of H2O2-injured MES23.5 cells, inhibited pro-apoptotic FasL and caspase-3 expression, promoted anti-apoptotic Bcl-2 expression. However, drug-containing serums had little influence on Fas expression in H2O2-injured MES23.5 cells. Enzyme-linked immunosorbent assay results showed that serum containing Herba Cistanches or Herba Epimedii increased the expression of nerve growth factor,brain-derived neurotrophic factor, and glial cell line-derived neurotrophic factor in injured MES23.5cells; serum containing Semen Cuscutae only increased brain-derived neurotrophic factor expression; while expression of the above neurotrophic factors remained the same in cells treated with serum containing selegiline. These findings indicate that Chinese medicines used to tonify the kidney can protect nerve cells by regulating the expression of apoptosis-related factors and neurotrophic factors in MES23.5 cells. | Shaogang Lin Shuifen Ye Jinmu Huang Yun Tian Yihui Xu Mengqi Wu Jingxia Wang Songying Wu Jing Cai | 2013 | Neural Regeneration Research2013，8，30： | 9 |
| 2 | The TAK1-JNK cascade is required for IRF3 function in the innate immune response显示文摘干扰素规章的因素(IRF ) 3 在病毒或细菌的侵略期间为 chemokines 和 cytokines 的 transcriptional 正式就职是批评的。kinases 坦克有约束力的 kinase (TBK ) 1 并且 Ikappa B kinase (IKK ) 蔚罐头 phosphorylate IRF3 和玩的 C 终端部分在 IRF3 激活的重要角色。在这研究,我们显示出那另外一个 kinase, c-Jun-NH2-terminal kinase (JNK ) ,它的 N 终端丝氨酸上的 phosphorylates IRF3 173 残余,和 TAK1 能经由 JNK 刺激 IRF3 phosphorylation。没有影响 C 终端 phosphorylation, JNK 特定的禁止者 SP600125 禁止 N 终端 phosphorylation。另外, lipopolysaccharide (LPS ) 上的调停 IRF3 的基因表情或 polyinosinic-cytidylic 酸(polyI : C ) 处理被 SP600125 严重地损害,以及为 IRF3 激活的记者基因试金。进一步证实的 TAK1 击倒这些观察。有趣地,组成的活跃 IRF3 (5D ) 能被 SP600125 禁止;JNK1 罐头 synergize IRF3 (5D ) 的行动,然而并非 S173A-IRF3 (5D ) 变异。更重要地, polyI : 没能戏剧性地导致变异的 S173A 和 SP600125 的 phosphorylation 的 C 废除了被 polyI 刺激的 IRF3 phosphorylation 和 dimerization : C。因此,这研究证明 TAK1-JNK 串联为 IRF3 功能被要求,除了 TBK1/IKK 蔚,揭开为激活 mitogen 的蛋白质(地图) 的新机制调整天生的免疫的 kinase。 | Bianhong Zhang Meng Li Liang Chen Kai Yang Yufei Shan Lianhui Zhu Shaogang Sun Lin Li Chen Wang | 2009 | Cell Research2009，19，4： | 4 |
| 3 | Survival after radical cystectomy for bladder cancer:Multicenter comparison between minimally invasive and open approaches显示文摘Objective:To investigate oncological outcomes in patients with bladder cancer who underwent minimally invasive radical cystectomy(MIRC)or open radical cystectomy(ORC).Methods:We identified patients with bladder cancer who underwent radical cystectomy(RC)in 13 centers of the Chinese Bladder Cancer Consortium(CBCC).Perioperative outcomes were compared between MIRC and ORC.The influence of surgical approaches on overall survival(OS)and cancer-specific survival(CSS)in the entire study group and subgroups classified according to pathologic stage or lymph node(LN)status was assessed with the log-rank test.Multivariable Cox proportional hazard models were used to evaluate the association among OS,CSS and risk factors of interest.Results:Of 2098 patients who underwent RC,1243 patients underwent MIRC(1087 laparoscopic RC and 156 robotic-assisted RC,respectively),while 855 patients underwent ORC.No significant differences were noted in positive surgical margin rate and 90-day postoperative mortality rate.MIRC was associated with less estimated blood loss,more LN yield,higher rate of neobladder diversion,longer operative time,and longer length of hospital stay.There was no significant difference in OS and CSS according to surgical approaches(pZ0.653,and 0.816,respectively).Subgroup analysis revealed that OS and CSS were not significantly different regardless of the status of extravesical involvement or LN involvement.Multivariable Cox regression analyses showed that the surgical approach was not a significant predictor of OS and CSS.Conclusions:Our study showed that MIRC was comparable to conventional ORC in terms of OS and CSS. | Weibin Xie Junming Bi Qiang Wei Ping Han Dongkui Song Lei Shi Dingwei Ye Yijun Shen Xin Gou Weiyang He Shaogang Wang Zheng Liu Jinhai Fan Kaijie Wu Zhiwen Chen Xiaozhou Zhou Chuize Kong Yang Liu Chunxiao Liu Abai Xu Baiye Jin Guanghou Fu Wei Xue Haige Chen Tiejun Pan Zhong Tu Tianxin Lin Jian Huang | 2020 | Asian Journal of Urology2020，7，3： | 1 |
| 4 | Real-world effectiveness and safety of goserelin 10.8-mg depot in Chinese patients with localized or locally advanced prostate cancer显示文摘Objective:Real-word data on long-acting luteinizing hormone-releasing hormone(LHRH)agonists in Chinese patients with prostate cancer are limited.This study aimed to determine the real-world effectiveness and safety of the LHRH agonist,goserelin,particularly the long-acting 10.8-mg depot formulation,and the follow-up patterns among Chinese prostate cancer patients.Methods:This was a multicenter,prospective,observational study in hormone treatment-na?ve patients with localized or locally advanced prostate cancer who were prescribed goserelin 10.8-mg depot every 12 weeks or 3.6-mg depot every 4 weeks with or without an anti-androgen.The patients had follow-up evaluations for 26 weeks.The primary outcome was the effectiveness of goserelin in reducing serum testosterone and prostate-specific antigen(PSA)levels.The secondary outcomes included testosterone and PSA levels,attainment of chemical castration(serum testosterone<50 ng/d L),and goserelin safety.The exploratory outcome was the monitoring pattern for serum testosterone and PSA.All analyses were descriptive.Results:Between September 2017 and December 2019,a total of 294 eligible patients received≥1 dose of goserelin;287 patients(97.6%)were treated with goserelin 10.8-mg depot.At week 24±2,the changes from baseline[standard deviation(95%confidence interval)]in serum testosterone(n=99)and PSA(n=131)were-401.0 ng/d L[308.4 ng/d L(-462.5,-339.5 ng/d L)]and-35.4 ng/m L[104.4 ng/m L(-53.5,-17.4 ng/m L)],respectively.Of 112 evaluable patients,100(90.2%)achieved a serum testosterone level<50 ng/d L.Treatment-emergent adverse events(TEAEs)and severe TEAEs occurred in 37.1%and 10.2%of patients,respectively.The mean testing frequency(standard deviation)was 1.6(1.5)for testosterone and 2.2(1.6)for PSA.Conclusions:Goserelin 10.8-mg depot effectively achieved and maintained castration and was well-tolerated in Chinese patients with localized and locally advanced prostate cancer. | Nanhui Chen Zengjun Wang Ming Chen Qi Ma Yi He Yujie Wang Xin Li Mingxing Qiu Lei Shi Shaoxing Zhu Qun Xie Xiuheng Liu Benkang Shi Guowen Lin Weizhong Yang Yongbin Liao Haibin Zhang Shusheng Wang Jiexian Li Shaogang Wang Lijun Dong Hui Chen Jiaju Lu YongyiCheng Xiaoping Zhang Lulin Ma Liqun Zhou He Wang Shen Li Dingwei Ye | 2023 | Cancer Biology & Medicine2023，20，12： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员